Alessandro Libra

Dr. Alessandro Libra

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
FGFederica Galioto
Federica Galioto
Stefano PalmucciStefano Palmucci
Stefano Palmucci
GAGiovanna M. Astuti
Giovanna M. Astuti
AVAda Vancheri
Ada Vancheri
GDGiulio Distefano
Giulio Distefano
CVCarlo Vancheri
Carlo Vancheri
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with uncertain origins and pathogenesis; it represents the most common interstitial lung disease (ILD), associated with a pathological pattern of usual interstitial pneumonitis (UIP). This disease has a poor prognosis, having the most lethal prognosis among ILDs. In fact, the progressive fibrosis related to IPF could lead to the development of complications, such as acute exacerbation, lung cancer, infections, pneumothorax and pulmonary hypertension. Pneumologists, radiologists and pathologists play a key role in the identification of IPF disease, and in the characterization of its complications—which unfortunately increase disease mortality and reduce overall survival. The early identification of these complications is very important, and requires an integrated approach among specialists, in order to plane the correct treatment. In some cases, the degree of severity of patients having IPF complications may require a personalized approach, based on palliative care services. Therefore, in this paper, we have focused on clinical and radiological features of the complications that occurred in our IPF patients, providing a comprehensive and accurate pictorial essay for clinicians, radiologists and surgeons involved in their management.

25 April 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
DSDomenico Sambataro
Domenico Sambataro
Gianluca SambataroGianluca Sambataro
Gianluca Sambataro
ALAlessandro Libra
Alessandro Libra
GVGiovanna Vignigni
Giovanna Vignigni
FPFabio Pino
Fabio Pino
CVCarlo Vancheri
Carlo Vancheri
Nailfold videocapillaroscopy (NVC) is an easy tool used for the assessment of patients with Raynaud’s phenomenon (RP) as possibly associated with systemic sclerosis (SSc). Recent insights have also highlighted its role in the diagnostic assessment of idiopathic inflammatory myopathies (IIMs). The aim of this study is to describe the diagnostic role of NVC in a series of 361 consecutive patients with interstitial lung disease (ILD). All the patients were assessed by clinical pulmonary and rheumatic examinations, blood exams, high-resolution computed tomography and NVC. NVC was considered positive only in the presence of avascular areas or giant capillaries, but also, the presence of bushy capillaries (BCs) was recorded. NVC was positive in 17.7% of ILD patients and in 78.1% of ILD patients associated with a diagnosis of connective tissue disease (CTD). In 25% of SSc-ILD patients, NVC proved necessary for a correct diagnosis. The presence of BCs and/or NVC positivity in ILD patients with normal levels of creatine phosphokinase is associated with amyopathic IIM, regardless the presence of RP. In conclusion, NVC is useful for the diagnostic assessment of incomplete forms of CTD and in amyopathic IIMs. NVC should be considered in the diagnostic assessment of ILD patients regardless of the presence of RP.

Verified
Journal Article
Open access
PDF file
ALAlessandro Libra
Alessandro Libra
ESEnrico Sciacca
Enrico Sciacca
GMGiuseppe Muscato
Giuseppe Muscato
Gianluca SambataroGianluca Sambataro
Gianluca Sambataro
LSLucia Spicuzza
Lucia Spicuzza
CVCarlo Vancheri
Carlo Vancheri
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by irreversible scarring of lung tissue, leading to death. Despite recent advancements in understanding its pathophysiology, IPF remains elusive, and therapeutic options are limited and non-curative. This review aims to synthesize the latest research developments, focusing on the molecular mechanisms driving the disease and on the related emerging treatments. Unfortunately, several phase 2 studies showing promising preliminary results did not meet the primary endpoints in the subsequent phase 3, underlying the complexity of the disease and the need for new integrated endpoints. IPF remains a challenging condition with a complex interplay of genetic, epigenetic, and pathophysiological factors. Ongoing research into the molecular keystones of IPF is critical for the development of targeted therapies that could potentially stop the progression of the disease. Future directions include personalized medicine approaches, artificial intelligence integration, growth in genetic insights, and novel drug targets.

10 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ALAlessandro Libra
Alessandro Libra
MCMichele Colaci
Michele Colaci
LSLucia Spicuzza
Lucia Spicuzza
GLGiuliana Luca
Giuliana Luca
SFSefora Fischetti
Sefora Fischetti
Gianluca SambataroGianluca Sambataro
Gianluca Sambataro
Background: We proposed the term “UIPAF” to define patients with Usual Interstitial Pneumonia (UIP) associated with only one domain of the classification called “Interstitial Pneumonia with Autoimmune Features” (IPAF). The objective of this study was to evaluate the clinical presentation and prognosis of UIPAF patients, compared with two cohorts, composed of IPAF and idiopathic pulmonary fibrosis (IPF) patients, respectively. Methods: The patients were enrolled as IPAF, UIPAF, or IPF based on clinical, serological, and radiological data and evaluated by a multidisciplinary team. Results: We enrolled 110 patients with IPF, 69 UIPAF, and 123 IPAF subjects. UIPAF patients were similar to IPAF regarding autoimmune features, except for the prevalence of Rheumatoid Factor in UIPAF and anti-SSA in IPAF. A similar proportion of the two cohorts progressed toward a specific autoimmune disease (SAD), with differences in the kind of SAD developed. The real-life management and prognosis of UIPAF patients proved to be almost identical to IPF. Conclusions: UIPAF shared with IPAF similar autoimmune features, suggesting the opportunity to be considered IPAF, excluding the morphological domain by the classification. However, the real-life management and prognosis of UIPAF are similar to IPF. These data suggest a possible modification in the therapeutic management of UIPAF.

27 November 2025 in Respiratory Medicine
Verified
Journal Article
Open access
SMSalvatore Mancuso
Salvatore Mancuso
DCDomenico Caratozzolo
Domenico Caratozzolo
ALAlessandro Libra
Alessandro Libra
CPChiara Pasquali
Chiara Pasquali
GMGiuseppe Muscato
Giuseppe Muscato
LSLucia Spicuzza
Lucia Spicuzza
Telemedicine is an essential tool to follow patients with obstructive sleep apnea (OSA) on CPAP. to establish whether in patients with OSA a 12-month follow-up program by a remote medical centre (RMC), functioning as an intermediary between patients and OSA Unit (OU), affects CPAP use compared to patients on usual care (UC). in a randomized controlled trial we enrolled 91 patients initiating CPAP in the RMC group and 101 in the UC group. The RMC performed all interventions remotely. Primary outcomes were nightly hours of CPAP use and adherence. in patients with initial adaptation difficulties (<4h night) mean nightly use of CPAP increased (1th to 12th month) from 2.5±0.8 to 4.3±1.6 h (P4h CPAP use also significantly increased from 9.4±7.7 to 17.7±8.9 (P<0.0001) in the RMC group but not in the UC group. The percentage of patients with an improvement in adherence after 12 months was 34.2% RMC vs 16.4% UC, P<0.05. Patients whose adherence worsened were 11.8% RMC and 19.3% UC (P<0.05). None of the patients followed at a distance required face-to-face visit for the duration of the study. long-term telemedicine follow-up compared to standard care is effective in improving adherence to CPAP in patients with initial CPAP adaptation difficulties. The follow-up by a RMC outside the OU can be considered a safe and effective option to reduce the workload of the staff in the OU.

27 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ALAlessandro Libra
Alessandro Libra
GMGiuseppe Muscato
Giuseppe Muscato
GIGiuseppe Ielo
Giuseppe Ielo
LSLucia Spicuzza
Lucia Spicuzza
Stefano PalmucciStefano Palmucci
Stefano Palmucci
CVCarlo Vancheri
Carlo Vancheri
Perinuclear Anti Neutrophil Cytoplasmic Antibody (p-ANCA) is a serological marker of Microscopic Polyangiitis (MPA), a vasculitis associated with lung involvement potentially mimicking Idiopathic Pulmonary Fibrosis (IPF). In this study, we evaluated the role of p-ANCA in predicting clinical evolution and prognosis in a cohort of IPF patients. In this observational, retrospective, case–control study, we compared 18 patients with an IPF diagnosis and p-ANCA positivity with 36 patients with seronegative IPF, matched for age and sex. IPF patients with and without p-ANCA showed similar lung function decline during the follow-up, but IPF p-ANCA+ showed better survival. Half of IPF p-ANCA+ patients were classified as MPA for the development of renal involvement (55%) or skin signs (45%). The progression towards MPA was associated with high levels of Rheumatoid Factor (RF) at baseline. In conclusion, p-ANCA, mainly when associated with RF, could predict the evolution of Usual Interstitial Pneumonia (UIP) towards a definite vasculitis in patients, with a better prognosis compared with IPF. In this view, ANCA testing should be included in the diagnostic workup of UIP patients.